Bayer’s Vividion Signs US$930 M Cancer Collaboration with Tavros Therapeutics
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 15 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2735 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
On the hunt for undruggable targets, Vividion Therapeutics has entered into a collaboration with Tavros Therapeutics to identify four cancer targets, with an option to pursue up to five more...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS